Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as "Precision Medical") was listed on the Hong Kong Stock Exchange, closing at HKD 56.6, a rise of 30.90% from its initial offering price of HKD 43.24 [1][4]. Group 1: IPO Details - The total number of shares offered globally was 27,722,200 H-shares, with 2,772,300 shares available for public offering in Hong Kong and 24,949,900 shares for international offering [2]. - The total amount raised from the offering was HKD 1,198.7 million, with net proceeds of HKD 1,116.6 million after deducting estimated listing expenses of HKD 82.1 million [4][6]. Group 2: Use of Proceeds - Approximately 23.0% of the net proceeds will fund research and development for the multi-port surgical robot, 19.0% for the single-port surgical robot, and 20.0% for the commercialization of core products [6]. - Additional allocations include 10.0% for capacity expansion, 8.0% for other products and ongoing research, 10.0% for potential strategic acquisitions or investments in the surgical robot industry, and 10.0% for working capital and general corporate purposes [6]. Group 3: Financial Performance - Precision Medical's revenues for 2023, 2024, and the first half of 2025 were HKD 48.0 million, HKD 160.0 million, and HKD 149.4 million, respectively, with losses of HKD 212.9 million, HKD 218.5 million, and HKD 89.1 million during the same periods [9][10]. - Cumulative losses for the years 2023 to the first half of 2025 totaled HKD 520 million [9]. Group 4: Key Investors - Major cornerstone investors include ADIA, UBS AM Singapore, OrbiMed Genesis, Tencent's Huang River Investment Limited, and several other investment funds [7][8].
精锋医疗港股募12亿港元首日涨30.9% 两年半亏5亿元